Document Detail


Pigment epithelium-derived factor (PEDF) increases in type 2 diabetes after treatment with metformin.
MedLine Citation:
PMID:  22248012     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Objective:  Pigment epithelium-derived factor (PEDF) has anti-angiogenic, immunomodulatory and anti-inflammatory properties. In addition to the significant role it plays in reducing diabetic complications, PEDF is now used in the treatment of certain cancers. It possibly plays a role in insulin resistance cases, too. However, whether metformin treatment has any significant effects on PEDF levels is not known. In this study, we investigated the regulation of PEDF in type 2 diabetes in relation to fat mass and insulin resistance before and after the use of metformin for treatment. Design:  Prospective cohort study Subjects:  Thirty six patients with newly-diagnosed type 2 diabetes and 33 healthy individuals Measurements:  Baseline weight, waist circumference (WC), fasting (FPG) and postprandial (PPPG) glucose, insulin, HbA1c, HOMA, PEDF, total/truncal fat mass were determined both in the diabetic and control subjects. Procedures were repeated in the diabetic group after a 6-month metformin treatment. Results:  Baseline FPG, PPPG, HbA1c, HOMA, weight, WC and truncal fat mass were higher in diabetic patients whereas PEDF levels were found to be comparable with the controls. We completed the study with 31 of the 36 diabetic patients we had selected for the study. We observed a decrease in the weight, WC, FPG, PPPG, HOMA, total and truncal fat mass of the patients while there was a significant rise in the PEDF levels (p=0.002) after the metformin treatment. On the other hand, no significant correlation was observed between the change in PEDF levels, and the clinical and laboratory findings. Conclusion:  Our study is the first to identify a metformin related increase in PEDF levels in diabetes. The increase observed in PEDF levels after the metformin treatment does not seem to be related to the changes in insulin resistance, fat mass or glycemic control. Hence, our results suggest that further investigation is necessary to determine the direct effects of metformin on PEDF gene and protein expression in vitro. © 2012 Blackwell Publishing Ltd.
Authors:
Safak Akın; Duygu Yazgan Aksoy; Neşe Cınar; Kadriye Aydın; Ergun Karaağaoğlu; Macit Arıyürek; Neşe Ersöz Gülçelik; Aydan Usman; Alper Gürlek
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-1-16
Journal Detail:
Title:  Clinical endocrinology     Volume:  -     ISSN:  1365-2265     ISO Abbreviation:  -     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-1-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Blackwell Publishing Ltd.
Affiliation:
Department of Internal Medicine, Section of Endocrinology and Metabolism Department of Biostatistics Department of Radiology, Hacettepe University, Faculty of Medicine, Ankara, Turkey Deparment of Internal Medicine and Endocrinology, Ministry of Health Etlik Education and Research Hospital, Ankara, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Undergraduate student drinking and related harms at an Australian university: web-based survey of a ...
Next Document:  A Review of Surgical Techniques for Impending Distal Erosion and Intraoperative Penile Implant Compl...